The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Document Type: Research Article
Affiliations: 1: Médecins Sans Frontières, Khayeltisha 2: TB Proof, Cape Town 3: Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa 4: Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa 5: Stop TB Partnership, Geneva, Switzerland 6: Desmond Tutu TB Center, Stellenbosch University, Cape Town, South Africa 7: Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts 8: HIV/TB Project, Treatment Action Group, New York, New York 9: Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA 10: Centre for International Health, Imperial College, London, UK 11: College of Liberal Arts and Sciences, Wayne State University, Detroit, Michigan, USA 12: TB Proof, Cape Town, Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa
Publication date: 01 November 2017
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites